leisure time -WSS

leisure time

author：leisure time 2025-10-01 23:31:15 - browse：877

BARCELONA, Spain — Some of the patients waiting in the oncology ward of a hospital here, with its green-tiled floor and white walls, had arrived for a newfangled remedy for blood cancers, what’s known as a CAR-T therapy.

The patients were not here for one of the brand-name medicines — a Kymriah or Yescarta — that have shown the power of these cell-based approaches and helped reap their makers hundreds of millions of dollars. Rather, they would be receiving a CAR-T brewed up right here at Hospital Clínic de Barcelona.

Under a special European policy, the CAR-T developed by the hospital’s experts had won regulatory approval in Spain and was reimbursed by the national health system like other authorized medications. The therapy provided another option for patients, all at a price of 89,000 euros ($97,000), roughly a third of the list prices of the CAR-T products from biopharma companies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Change Healthcare can notify patients about the breach, HHS says

knowledge

WSS

Alcohol isn't healthy after all. Will new dietary guidelines reflect that?

At ASCO, AstraZeneca reports strong data for breast cancer drug

Google says AlphaFold 3 can map a vast universe of biomolecules

What nurses really want: sufficient staffing for patient care

See how much Covid

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

knowledge

leisure time

focus

Affirmative action in medical school literally saved lives

Letters to First Opinion on caregivers, digital health, and more

What does generative AI mean for health care? We asked experts

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

United colonoscopy coverage change 'may cost lives,' doctors say

Bird flu outbreak in cows is latest avian flu curveball

As demand for Covid shots wanes, Moderna seeks its next success

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Hepatitis C has a cure — but many Americans still lack access to it

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Wikipedia

Brain worms: The science behind RFK Jr.'s parasitic infection

Let's speed up science by embracing open access publishing

FDA's Pazdur wants cancer trials to range beyond China alone

At ASCO, AstraZeneca reports strong data for breast cancer drug

At ASCO, AstraZeneca reports strong data for breast cancer drug

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

hotspot

knowledge

focus

explore